Simplify Logo
Evolent

Evolent

Delivers value-based care through analytics

Medical Director - Vascular Surgery

Full-Time
$130 - $140/hr
Senior
MD
Remote in USA
Remote
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • An MD, DO, or MBBS degree is required.
  • A current, unrestricted clinical license in medicine or the required specialty is required.
  • The physician must obtain and maintain medical licenses in the state where they reside.
  • Active board certification in Vascular Surgery, or active board certification in General Surgery with extensive experience in Vascular Surgery, is required.
  • Strong clinical, management, communication, and organizational skills are required.
  • Computer proficiency is required.
  • High-speed internet over 10 Mbps is required at the employee's home, and call-center employees must be able to connect directly to the home internet router.
  • Candidates must complete identity verification, a comprehensive background check, and in-person I-9 verification; drug screening may also be required before employment.
Responsibilities
  • Serve as the specialty-match reviewer for Vascular cases that do not initially meet applicable medical-necessity guidelines, as well as other imaging requests requiring specialty review.
  • Discuss determinations with requesting physicians or ordering providers through peer-to-peer phone calls within the applicable regulatory timeframe.
  • Provide clinical rationale for standard and expedited appeals.
  • Use medical and clinical review guidelines and parameters to ensure consistency in the physician review process and compliance with organizational policies and procedures, Utilization Review Accreditation Commission guidelines, and National Committee for Quality Assurance guidelines.
  • Aid and act as a resource to Initial Clinical Reviewers.
  • Ensure that communications with medical office staff and physician providers are documented accurately and in a timely manner.
  • Participate in ongoing training under the inter-rater reliability process.
  • Assist the Senior Medical Director with research activities and questions related to utilization management, interpretation, guidelines, or system support when requested.
  • Function as Medical Director for selected health plans or regions when requested, assuming overall accountability for utilization management in conjunction with the Senior Medical Director.
Desired Qualifications
  • A minimum of five years of experience practicing as a vascular surgeon is preferred.

About the company

Evolent Health helps healthcare organizations transition to value-based care by pairing technology, analytics, and clinical expertise to improve patient outcomes while lowering costs. It partners with health systems, physician groups, and health plans to deliver data-driven care coordination, population health management, and risk-adjustment services. The company’s offerings include software platforms, analytics, and clinical support that enable more efficient care delivery, shared savings programs, and performance-based incentives. Compared with competitors, Evolent emphasizes end-to-end collaboration with clients and a diversified client base, combining technology with hands-on clinical and operational expertise to drive measurable outcomes. Its goal is to help clients succeed in value-based models by delivering better patient care at lower total costs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Arlington, Virginia

Founded

2011

Get referred to Evolent

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $652.5 million, and guidance rose to $2.65 billion.
  • Highmark launched May 1, 2026, and Aetna metrics exceeded targets in Q2.
  • Management expects 2027 revenue growth above 25%, backed by renewals and oncology expansion.

What critics are saying

  • Evolent carried $966.5 million debt on June 30, 2026, squeezing refinancing flexibility.
  • Management expects a 40% exchange-membership decline in 2026, pressuring Specialty T&S revenue.
  • The $398 million 2025 goodwill impairment exposes fragile asset values if August 2026 margins weaken.

What makes Evolent unique

  • Evolent pairs oncology Performance Suite with payer integrations, spanning Highmark, Aetna, and Blue Cross.
  • Archie Mayani joined March 2026, accelerating Auth Intelligence and AI-enabled prior authorization.
  • Evolent sells risk-bearing clinical workflows, not generic software, embedding into payer economics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Hybrid Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 15th, 2026
Evolent Health beats Q2 revenue estimates by 9.4%, raises full-year guidance to $2.65B

Evolent Health reported strong second-quarter results, beating revenue expectations with $652.5 million versus the anticipated $596.7 million, representing 46.9% year-on-year growth. The company also surpassed adjusted earnings per share and EBITDA forecasts. CEO Seth Blackley attributed the performance to successful contract launches with Highmark and robust customer renewals. Clinical engagement metrics for new partnerships with Aetna and Highmark exceeded targets, demonstrating strong execution in value-based care solutions. The company raised its full-year revenue guidance to $2.65 billion at the midpoint, up 6% from the previous $2.5 billion forecast. EBITDA guidance remained at $127.5 million. During the earnings call, management addressed analyst questions about reserving processes, margin trends in new contracts, and pipeline development. Blackley noted the business pipeline has refilled with several large national plans under consideration, particularly in oncology services.

Yahoo Finance
Aug 10th, 2026
Evolent Health beats revenue estimates with $652.5M, raises full-year guidance to $2.65B on AI automation gains

Evolent Health reported Q2 2026 revenue of $652.5 million, up 46.9% year-on-year and beating analyst estimates by 9.4%. The healthcare solutions company's full-year revenue guidance of $2.65 billion came in 5.9% above consensus. CEO Seth Blackley highlighted the successful launch of the Highmark contract and strong clinical engagement metrics for new partnerships with Aetna and Highmark. The company's Auth Intelligence automation platform contributed to operational efficiency gains. Management pointed to expansion of its oncology Performance Suite and accelerated deployment of its AI-enabled authorisation platform as key growth drivers. Blackley stated Q2 represented "a tipping point in our AI journey" as efforts moved beyond pilot phases to meaningful scale. The company expects cost-saving initiatives and improved operating leverage to offset headwinds from Medicaid and exchange membership pressures.

Yahoo Finance
Aug 6th, 2026
Evolent Health revenue surges 31% to $653M, raises 2026 guidance to $2.7B

Evolent Health reported strong second-quarter 2026 results, with total revenue reaching $653 million, up 31% from the previous quarter. Adjusted EBITDA rose 27% quarter-over-quarter to $28 million. The healthcare technology company raised its full-year 2026 revenue guidance to between $2.6 billion and $2.7 billion. It tightened adjusted EBITDA guidance to a range of $120 million to $135 million. Evolent announced a new oncology Performance Suite partnership covering approximately 1.5 million lives across 11 states, expected to generate about $300 million in annualised revenue. The company also secured a contract extension with a regional Blue Cross plan. The firm ended Q2 with $115.7 million in unrestricted cash and $808.3 million of net debt. For 2027, Evolent expects revenue growth exceeding 25%.

Yahoo Finance
Jun 12th, 2026
Evolent Health posts weakest Q1 revenue growth among healthcare tech providers despite $496M earnings

Evolent Health reported Q1 revenues of $496.2 million, up 2.6% year on year, but falling short of analysts' expectations by 6.9%. The healthcare technology company, which provides specialty care management services for patients with complex conditions, delivered mixed results with an earnings per share beat but a significant revenue miss. The healthcare technology for providers sector showed overall strength in Q1, with the four tracked stocks beating revenue consensus estimates by 1.1% on average. Share prices have risen 7.7% on average since earnings results. Despite having the weakest performance against analyst estimates and slowest revenue growth in the group, Evolent Health raised its full-year guidance the most. The stock has climbed 21.5% since reporting and currently trades at $4.65.